Genfit

Genfit est une société de biotechnologie française. Ses recherches et essais cliniques, dans les domaines des maladies cardio-vasculaires et des maladies du foie, notamment d'origine métabolique, n'ont pas permis, depuis 1999, la mise sur le marché d'un médicament.

Filings

100 filings

All Inside information68 Earnings release9 Share buyback8 Universal registration document6 Threshold crossing4 Half-year financial report3 AGM documents2

08/07/2026
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Share buybackFR
02/07/2026
GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
Inside informationFR
23/06/2026
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
Inside informationFR
15/06/2026
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
Inside informationFR
08/06/2026
GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
Inside informationFR
25/05/2026
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
Inside informationFR
21/05/2026
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
Inside information
21/05/2026
GENFIT : Information financière du premier trimestre 2026 et point sur les activités de la Société
Earnings releaseFrench
11/05/2026
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
AGM documentsFR
20/04/2026
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
Inside information
20/04/2026
GENFIT : Publication du rapport de performance extra-financière 2026 (exercice 2025)
Earnings releaseFrench
07/04/2026
GENFIT Announces Publication of the 2025 Universal Registration Document
Universal registration documentFR
03/04/2026
Document d'Enregistrement Universel 2025
Universal registration documentFrench
02/04/2026
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
Earnings releaseFR
09/03/2026
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
Inside informationFR
02/03/2026
Franchissements de seuil
Threshold crossingFrench
02/03/2026
Franchissement de seuil
Threshold crossingFrench
26/02/2026
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
Inside informationFR
12/02/2026
GENFIT va recevoir un paiement d’étape de 20 M$ suite au dépassement du seuil des 200 M$ de ventes nettes d’Iqirvo® par Ipsen dès sa première année complète de commercialisation
Inside informationFrench
12/02/2026
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
Earnings release
20/01/2026
Franchissement de seuil
Threshold crossingFrench
19/01/2026
Franchissement de seuil
Threshold crossingFrench
13/01/2026
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Share buybackFR
07/01/2026
GENFIT Announces 2026 Financial Calendar
Inside informationFR
06/01/2026
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
Inside informationFR
10/12/2025
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
Inside informationFR
27/11/2025
GENFIT Announces Appointment of new Chief Medical Officer
Inside informationFR
20/11/2025
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
Inside informationFR
20/11/2025
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
Inside informationFR
10/11/2025
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
Inside informationFR
10/11/2025
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
Inside informationFR
30/10/2025
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
Inside informationFR
28/10/2025
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
Inside informationFR
22/09/2025
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
Inside information
22/09/2025
GENFIT : Résultats financiers du premier semestre 2025 et point sur les activités de la Société
Earnings releaseFrench
22/09/2025
Attestation de la personne responsable associée au rapport d'activité et financier semestriel 2025
Half-year financial reportFrench
22/09/2025
Rapport des CAC associé au rapport d'activité et financier semestriel 2025
Half-year financial reportFrench
22/09/2025
Rapport d'activité financier et semestriel 2025
Half-year financial reportFrench
19/09/2025
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
Inside informationFR
08/07/2025
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Share buybackFR
17/06/2025
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
Inside informationFR
22/05/2025
GENFIT Reports First Quarter 2025 Financial Information
Inside information
22/05/2025
GENFIT : Information financière du premier trimestre 2025
Earnings releaseFrench
20/05/2025
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
Inside informationFR
14/05/2025
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
Inside information
07/05/2025
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents
Inside informationFR
05/05/2025
GENFIT to Present Latest ACLF Research at EASL Congress 2025
Inside informationFR
29/04/2025
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
Universal registration documentFR
29/04/2025
Document d'Enregistrement Universel 2024
Universal registration documentFrenchZIP
28/04/2025
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
Inside informationFR

About

ISIN: FR0004163111
Ticker: GNFT
LEI: 969500XPWN2DMZQA5X73
Sector: Health care
Founded: 1999
Country of registration: FR
Last filing: 08/07/2026, 18:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive